News

Public · Published

CORT: Revenue rose 64% as Lifyorli adoption and oncology trial results strengthened growth prospects

Corcept Therapeutics reported third-quarter revenue of $340.5 million, up 64% from a year earlier, and net income of $126.8 million. It reiterated 2026 revenue guidance of $1.1 billion to $1.2 billion, citing Lifyorli launch adoption and BELLA Part A results as supporting oncology growth prospects.

Published:

Updated:

What happened

Corcept Therapeutics reported third-quarter revenue of $340.5 million, up 64% from a year earlier, and net income of $126.8 million. It reiterated 2026 revenue guidance of $1.1 billion to $1.2 billion, citing Lifyorli launch adoption and BELLA Part A results as supporting oncology growth prospects.

Confirmed

Global impact / market context

Higher revenue and net income indicate stronger recent business performance, while Lifyorli adoption and oncology trial results point to potential additional growth drivers. If those drivers translate into sustained sales, they could support future revenue and cash available; the reiterated 2026 outlook sets a benchmark for judging execution.

Analyst inference

The article combines reported quarterly results with a forward revenue range, but provides no sales breakdown, trial details, or comparison with prior expectations. Investors therefore have limited evidence here to assess how much growth came from Lifyorli or how reliably oncology prospects can contribute.

Analyst inference

What to watch

  1. Track whether upcoming reports show Lifyorli adoption continuing to add to revenue, since the article identifies launch uptake as one support for oncology growth prospects. Analyst inference
  2. Watch for further BELLA trial updates; Part A results are cited as supportive, but the article gives no details on findings or later trial steps. Confirmed
  3. Compare reported revenue with the reiterated 2026 range of $1.1 billion to $1.2 billion as new results emerge, to judge whether the outlook remains achievable. Analyst inference

Evidence

  • Original source link unavailable